Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 11/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952188 | 0.85 | IMPDH2 (0.39) | IMPDH2KDM4EALDH1A1GAASLC2A1 | |
| SCHEMBL9952242 | 0.84 | IMPDH2 (0.36) | IMPDH2ALDH1A1GAACYP1A2KMT2A | |
| SCHEMBL9953163 | 0.83 | IMPDH2 (0.37) | IMPDH2KDM4EALDH1A1GAASLC2A1 | |
| SCHEMBL9952629 | 0.81 | IMPDH2 (0.47) | IMPDH2KDM4EALDH1A1GAASLC2A1 | |
| SCHEMBL9952076 | 0.81 | IMPDH2 (0.47) | IMPDH2KDM4EALDH1A1GAASLC2A1 | |
| SCHEMBL20240848 | 0.80 | IMPDH2 (0.37) | IMPDH2KDM4EALDH1A1GAA | |
| SCHEMBL9953135 | 0.79 | IMPDH2 (0.36) | IMPDH2 | |
| SCHEMBL14742448 | 0.78 | IMPDH2 (0.45) | IMPDH2KDM4EALDH1A1GAASLC2A1 | |
| SCHEMBL20241159 | 0.77 | IMPDH2 (0.38) | IMPDH2KDM4EALDH1A1GAASLC2A1 | |
| SCHEMBL9953479 | 0.76 | TSHR (0.43) | IMPDH2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961410-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |